Slingshot members are tracking this event:

Phase 3 data of Revefenacin for COPD due fourth quarter 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
TBPH Community voting in process

Additional Information

Additional Relevant Details
Revefenacin: Two Phase 3 efficacy studies in COPD (2016)
Additional Relevant Details We anticipate the revefenacin Phase 3 program in COPD will read out data from the replicate three-month efficacy studies early in the fourth quarter of this year
Additional Relevant Details Update on 07/19/17: Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD)
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 20, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Data, Revefenacin, Copd